The FDA is holding a three-day advisory committee meeting to consider whether several early approved cancer drugs should remain on the market.
During the meetings, scheduled from April 27-29, the committee will hear updates on several cancer drugs that don't have verified clinical benefit, including Tecentriq from Merck and Opdivo from Bristol-Myers Squibb, among others.
The drug makers' updates will cover the "status and results of confirmatory clinical studies for a given indication," and "any ongoing and planned trials."
Based on the updates, the committee will determine whether the drugs should remain on the market while further trials are conducted.
For more details, click here.